NCT03191149 2026-04-14Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 ChangeNational Cancer Institute (NCI)Phase 2 Recruiting46 enrolled
NCT04181060 2026-04-13Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerNational Cancer Institute (NCI)Phase 3 Recruiting300 enrolled